Triple therapy and incidence of de novo cancer in renal transplant recipients
Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than th...
Gespeichert in:
| Veröffentlicht in: | British journal of surgery 1994-07, Vol.81 (7), p.985-986 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 986 |
|---|---|
| container_issue | 7 |
| container_start_page | 985 |
| container_title | British journal of surgery |
| container_volume | 81 |
| creator | Kehinde, E. O. Petermann, A. Morgan, J. D. Butt, Z. A. Donnelly, P. K. Veitch, P. S. Bell, P. R. F. |
| description | Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than those given prednisolone with cyclosporin (14 of 319; 4·4 per cent) and azathioprine with prednisolone (six of 133; 4·5 per cent) (P= 0·005). In a prospective study between January 1989 and December 1992, 110 renal transplant patients were randomized into three immunosuppressive regimens at the time of transplantation. The incidence of cancer in patients receiving low‐dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high‐dose cyclosporin and prednisolone none of 23 and in those administered high‐dose cyclosporin, nifedipine and prednisolone one of 29. The addition of azathioprine to ongoing maintenance cyclosporin and prednisolone therapy is useful in a subgroup of patients with graft dysfunction, but there are possibly higher risks in the development of de novo carcinoma. |
| doi_str_mv | 10.1002/bjs.1800810718 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmed_primary_7922092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BJS1800810718</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3688-c462fd0353a50e9e6cdedf6ec59d4d860e02e2c5ec76b1fa2786f31c7fcc5b9e3</originalsourceid><addsrcrecordid>eNpFkElPwzAQhS0EKqVw5YbkA9eUsV0vOUIFBVQWQRFHy7UnwhDSKA5L_z1BrdrTaOZ7bzTzCDlmMGQA_Gz-nobMABgGmpkd0mdCyYwzZXZJHwB0xgQX--QgpXcAJkDyHunpnHPIeZ_czZpYl0jbN2xcvaSuCjRWPgasPNJFQQPSavG9oN51g6ZjtMHKlbRtXJXq0lVtN_Cxjli16ZDsFa5MeLSuA_JydTkbX2fTh8nN-HyaeaGMyfxI8SKAkMJJwByVDxgKhV7mYRSMAgSO3Ev0Ws1Z4bg2qhDM68J7Oc9RDMjJam_9Nf_EYOsmfrpmaddvdfx0zV3yriy6W31MG9mIKWly1cnylewnlrjcYAb2P1rbRWu30dqL2-dt13mzlTemFn83Xtd8WKWFlvb1fmLHj1Oln-6v7VT8AZJZfLw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Triple therapy and incidence of de novo cancer in renal transplant recipients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kehinde, E. O. ; Petermann, A. ; Morgan, J. D. ; Butt, Z. A. ; Donnelly, P. K. ; Veitch, P. S. ; Bell, P. R. F.</creator><creatorcontrib>Kehinde, E. O. ; Petermann, A. ; Morgan, J. D. ; Butt, Z. A. ; Donnelly, P. K. ; Veitch, P. S. ; Bell, P. R. F.</creatorcontrib><description>Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than those given prednisolone with cyclosporin (14 of 319; 4·4 per cent) and azathioprine with prednisolone (six of 133; 4·5 per cent) (P= 0·005). In a prospective study between January 1989 and December 1992, 110 renal transplant patients were randomized into three immunosuppressive regimens at the time of transplantation. The incidence of cancer in patients receiving low‐dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high‐dose cyclosporin and prednisolone none of 23 and in those administered high‐dose cyclosporin, nifedipine and prednisolone one of 29. The addition of azathioprine to ongoing maintenance cyclosporin and prednisolone therapy is useful in a subgroup of patients with graft dysfunction, but there are possibly higher risks in the development of de novo carcinoma.</description><identifier>ISSN: 0007-1323</identifier><identifier>EISSN: 1365-2168</identifier><identifier>DOI: 10.1002/bjs.1800810718</identifier><identifier>PMID: 7922092</identifier><identifier>CODEN: BJSUAM</identifier><language>eng</language><publisher>Bristol: John Wiley & Sons, Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Azathioprine - adverse effects ; Biological and medical sciences ; Child ; Cyclosporine - adverse effects ; Drug Therapy, Combination ; Drug toxicity and drugs side effects treatment ; Female ; Follow-Up Studies ; Humans ; Immunosuppression - adverse effects ; Kidney Transplantation ; Male ; Medical sciences ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Neoplasms - etiology ; Pharmacology. Drug treatments ; Prednisolone - adverse effects ; Prospective Studies ; Time Factors</subject><ispartof>British journal of surgery, 1994-07, Vol.81 (7), p.985-986</ispartof><rights>Copyright © 1994 British Journal of Surgery Society Ltd.</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3688-c462fd0353a50e9e6cdedf6ec59d4d860e02e2c5ec76b1fa2786f31c7fcc5b9e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbjs.1800810718$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbjs.1800810718$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4165896$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7922092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kehinde, E. O.</creatorcontrib><creatorcontrib>Petermann, A.</creatorcontrib><creatorcontrib>Morgan, J. D.</creatorcontrib><creatorcontrib>Butt, Z. A.</creatorcontrib><creatorcontrib>Donnelly, P. K.</creatorcontrib><creatorcontrib>Veitch, P. S.</creatorcontrib><creatorcontrib>Bell, P. R. F.</creatorcontrib><title>Triple therapy and incidence of de novo cancer in renal transplant recipients</title><title>British journal of surgery</title><addtitle>Br J Surg</addtitle><description>Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than those given prednisolone with cyclosporin (14 of 319; 4·4 per cent) and azathioprine with prednisolone (six of 133; 4·5 per cent) (P= 0·005). In a prospective study between January 1989 and December 1992, 110 renal transplant patients were randomized into three immunosuppressive regimens at the time of transplantation. The incidence of cancer in patients receiving low‐dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high‐dose cyclosporin and prednisolone none of 23 and in those administered high‐dose cyclosporin, nifedipine and prednisolone one of 29. The addition of azathioprine to ongoing maintenance cyclosporin and prednisolone therapy is useful in a subgroup of patients with graft dysfunction, but there are possibly higher risks in the development of de novo carcinoma.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Azathioprine - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Cyclosporine - adverse effects</subject><subject>Drug Therapy, Combination</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunosuppression - adverse effects</subject><subject>Kidney Transplantation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Neoplasms - etiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisolone - adverse effects</subject><subject>Prospective Studies</subject><subject>Time Factors</subject><issn>0007-1323</issn><issn>1365-2168</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkElPwzAQhS0EKqVw5YbkA9eUsV0vOUIFBVQWQRFHy7UnwhDSKA5L_z1BrdrTaOZ7bzTzCDlmMGQA_Gz-nobMABgGmpkd0mdCyYwzZXZJHwB0xgQX--QgpXcAJkDyHunpnHPIeZ_czZpYl0jbN2xcvaSuCjRWPgasPNJFQQPSavG9oN51g6ZjtMHKlbRtXJXq0lVtN_Cxjli16ZDsFa5MeLSuA_JydTkbX2fTh8nN-HyaeaGMyfxI8SKAkMJJwByVDxgKhV7mYRSMAgSO3Ev0Ws1Z4bg2qhDM68J7Oc9RDMjJam_9Nf_EYOsmfrpmaddvdfx0zV3yriy6W31MG9mIKWly1cnylewnlrjcYAb2P1rbRWu30dqL2-dt13mzlTemFn83Xtd8WKWFlvb1fmLHj1Oln-6v7VT8AZJZfLw</recordid><startdate>199407</startdate><enddate>199407</enddate><creator>Kehinde, E. O.</creator><creator>Petermann, A.</creator><creator>Morgan, J. D.</creator><creator>Butt, Z. A.</creator><creator>Donnelly, P. K.</creator><creator>Veitch, P. S.</creator><creator>Bell, P. R. F.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>199407</creationdate><title>Triple therapy and incidence of de novo cancer in renal transplant recipients</title><author>Kehinde, E. O. ; Petermann, A. ; Morgan, J. D. ; Butt, Z. A. ; Donnelly, P. K. ; Veitch, P. S. ; Bell, P. R. F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3688-c462fd0353a50e9e6cdedf6ec59d4d860e02e2c5ec76b1fa2786f31c7fcc5b9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Azathioprine - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Cyclosporine - adverse effects</topic><topic>Drug Therapy, Combination</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunosuppression - adverse effects</topic><topic>Kidney Transplantation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Neoplasms - etiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisolone - adverse effects</topic><topic>Prospective Studies</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kehinde, E. O.</creatorcontrib><creatorcontrib>Petermann, A.</creatorcontrib><creatorcontrib>Morgan, J. D.</creatorcontrib><creatorcontrib>Butt, Z. A.</creatorcontrib><creatorcontrib>Donnelly, P. K.</creatorcontrib><creatorcontrib>Veitch, P. S.</creatorcontrib><creatorcontrib>Bell, P. R. F.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>British journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kehinde, E. O.</au><au>Petermann, A.</au><au>Morgan, J. D.</au><au>Butt, Z. A.</au><au>Donnelly, P. K.</au><au>Veitch, P. S.</au><au>Bell, P. R. F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triple therapy and incidence of de novo cancer in renal transplant recipients</atitle><jtitle>British journal of surgery</jtitle><addtitle>Br J Surg</addtitle><date>1994-07</date><risdate>1994</risdate><volume>81</volume><issue>7</issue><spage>985</spage><epage>986</epage><pages>985-986</pages><issn>0007-1323</issn><eissn>1365-2168</eissn><coden>BJSUAM</coden><abstract>Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than those given prednisolone with cyclosporin (14 of 319; 4·4 per cent) and azathioprine with prednisolone (six of 133; 4·5 per cent) (P= 0·005). In a prospective study between January 1989 and December 1992, 110 renal transplant patients were randomized into three immunosuppressive regimens at the time of transplantation. The incidence of cancer in patients receiving low‐dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high‐dose cyclosporin and prednisolone none of 23 and in those administered high‐dose cyclosporin, nifedipine and prednisolone one of 29. The addition of azathioprine to ongoing maintenance cyclosporin and prednisolone therapy is useful in a subgroup of patients with graft dysfunction, but there are possibly higher risks in the development of de novo carcinoma.</abstract><cop>Bristol</cop><pub>John Wiley & Sons, Ltd</pub><pmid>7922092</pmid><doi>10.1002/bjs.1800810718</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1323 |
| ispartof | British journal of surgery, 1994-07, Vol.81 (7), p.985-986 |
| issn | 0007-1323 1365-2168 |
| language | eng |
| recordid | cdi_pubmed_primary_7922092 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Azathioprine - adverse effects Biological and medical sciences Child Cyclosporine - adverse effects Drug Therapy, Combination Drug toxicity and drugs side effects treatment Female Follow-Up Studies Humans Immunosuppression - adverse effects Kidney Transplantation Male Medical sciences Middle Aged Miscellaneous (drug allergy, mutagens, teratogens...) Neoplasms - etiology Pharmacology. Drug treatments Prednisolone - adverse effects Prospective Studies Time Factors |
| title | Triple therapy and incidence of de novo cancer in renal transplant recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A20%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triple%20therapy%20and%20incidence%20of%20de%20novo%20cancer%20in%20renal%20transplant%20recipients&rft.jtitle=British%20journal%20of%20surgery&rft.au=Kehinde,%20E.%20O.&rft.date=1994-07&rft.volume=81&rft.issue=7&rft.spage=985&rft.epage=986&rft.pages=985-986&rft.issn=0007-1323&rft.eissn=1365-2168&rft.coden=BJSUAM&rft_id=info:doi/10.1002/bjs.1800810718&rft_dat=%3Cwiley_pubme%3EBJS1800810718%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7922092&rfr_iscdi=true |